HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... Falls Church, VA (PRWEB) , ... ... ... Device Clinical Evaluation Reports: Complying with European Guidelines and the New MEDDEV ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the ...
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After six years ... major victory in Europe for public health and the environment and is calling on ... scientific research and the overwhelming support of European citizens, the European Union (EU) will, ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “My Journey Through ... experience with an infinitely more profound faith of God’s promise of Heaven for His ... Jr., who spends each day with his wife, three children and six grandchildren living ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an ... published author, Scotty, a fiction writer with an active imagination and an enthusiasm for ... book follows the tale of Wild Bill Hart, who sat looking at the thirty-three ...
(Date:3/22/2017)... ... , ... Death anxiety is unconscious and needs understanding and non-judgmental support in ... write the book titled “ As Good as Goodbyes Get ” (published by Balboa ... she was experiencing at the bedside of patients who were dying. The book centers ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: ... integrated commercial company that provides clinically useful molecular ... it has entered into agreements to successfully restructure ... ("RedPath") and concurrently terminate its royalty and milestone ... debt to RedPath amounting to $9.34 million is ...
(Date:3/23/2017)... March 23, 2017 CENTRO DE IMAGEM DIAGNOSTICOS ... paragraph 4 of Law 6,404/76 and Instruction 358/02 of ... its shareholders and the market in general that it ... Centro de Diagnosticos por Imagem Ltda. (" CDI "), ... in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and " ...
(Date:3/23/2017)... 23, 2017  The goal of the pilot ... and track prescription drugs as they are distributed in ... to requirements from US FDA to better protect consumers ... medicines. Blockchain startup Chronicled, which links ... and blockchain technology and recently raised $6.25M, and the ...
Breaking Medicine Technology:
Cached News: